Every compound, with the data behind it

AMY-Cg

AMY-Cg (AM-833; CAS 1393461-38-5) is a synthetic, lipidated long-acting analogue of the pancreatic peptide hormone amylin, engineered for sustained activity at all three amylin receptor subtypes (AMY1R, AMY2R, AMY3R) and the calcitonin receptor (CTR) — classifying it as a dual amylin and calcitonin receptor agonist (DACRA). A C20 fatty diacid N-terminal lipidation strategy enables albumin binding, reducing plasma clearance and extending circulating half-life to approximately 159–195 hours (~7 days) in pharmacokinetic research studies. Targeted structural modifications (14E/17R salt-bridge substitutions; 25P/28P/29P proline substitutions) simultaneously prevent amyloid fibril formation. Cryo-EM structures published in Nature Communications (2025) resolve AMY-Cg bound to Gs-coupled active AMY1R, AMY2R, AMY3R, and CTR at atomic resolution. Preclinical research in RAMP1/3 knockout mouse models confirms that AMY-Cg's metabolic signalling effects are specifically dependent on intact AMY1R and AMY3R function in hindbrain neuronal circuits (area postrema/NTS). FOR RESEARCH USE ONLY. Not for consumption, human or animal administration, or any application outside a controlled non-clinical laboratory setting.

GLP-1-Sm

GLP-1-Sm is a long-acting GLP-1 receptor agonist derived from human GLP-1 and engineered for extended activity through DPP-4 resistance and albumin binding. Registered as PubChem CID 56843331 (C187H291N45O59; 4113.58 g/mol), it is the active pharmaceutical ingredient in Ozempic, Wegovy, and Rybelsus. This scientific reference resource provides molecular, pharmacological, and 2026 regulatory overview information for academic and professional use.

GLP/GIP-Tz

This is a Research Reagent designed strictly for laboratory Stock Solution Preparation, available in multiple mass formats from 5mg to 120mg. It features a lyophilized “cake” of the Dual-Agonist Ligand (GLP/GIP-Tz), allowing researchers to reconstitute a single, uniform batch for longitudinal metabolic studies at the scale their protocol requires. Higher-mass formats eliminate inter-batch variance found in smaller units when large stock volumes are needed. Not for human use.

GLP/GIP/GLC-Rt

GLP/GIP/GLC-Rt Research Grade (RUO) (CAS 2381089-83-2, LY3437943) is a 39–amino acid unimolecular peptide designed as a triple agonist for GIP / GLP-1 / Glucagon (GCG) receptors. Supplied as a lyophilized white powder with ≥99% purity (HPLC verified) and endotoxin <1.0 EU/mg, it is soluble in Solution. The molecule includes a C20 fatty diacid moiety for albumin binding and extended stability (reported ~6-day half-life), supporting metabolic, obesity, T2D, and hepatic defatting research models.For Research Use Only (RUO). Not for human or veterinary use.

Mazdu

Mazdu (Dual-A) is the high-affinity substrate required for isolating metabolic signaling pathways. Unlike mono-ligands (like GLP-1-Sm [Ref Std]), Mazdu (Dual-A) demonstrates simultaneous binding affinity for both the GLP-1 Receptor and the Glucagon Receptor (GCGR), facilitating complex Ex-vivo Research Protocols.

SKU MAZD-6MG-4183

Survo

Survo (BI 456906; CAS 2805997-46-8; PubChem CID 168429725) is a synthetic, acylated 29-amino-acid research peptide derived from the glucagon backbone, engineered as a dual agonist at glucagon receptors (GCGR) and GLP-1 receptors (GLP-1R). A C18 fatty diacid side chain at position 24, linked via a hydrophilic glycine-serine spacer, enables albumin binding for extended circulating presence and once-weekly research protocol administration. A non-coded amino acid (1-aminocyclobutane-1-carboxylic acid; Ac4c) at position 2 differentiates Survo from native glucagon and enhances receptor selectivity. Developed by Boehringer Ingelheim under licence from Zealand Pharma, Survo is in Phase 3 clinical research programmes (SYNCHRONIZE series for body-weight management; LIVERAGE programme for MASH) and holds FDA Breakthrough Therapy Designation for non-cirrhotic MASH with moderate to advanced fibrosis. It is not approved by the FDA for any indication as of March 2026. FOR RESEARCH USE ONLY. Not for consumption, human or animal administration, or any application outside a controlled non-clinical laboratory setting. Researchers require institutional approval, appropriate biosafety protocols, and batch COA documentation before any laboratory use.

TESOFENSINE (Research tablets)

Tesofensine, also known as NS-2330, is a synthetic small-molecule triple monoamine reuptake inhibitor registered under PubChem CID 11370864. It is not a peptide and is distinct from CJC-1295 or ipamorelin. Tesofensine is not FDA-approved as of 2026, while the Tesomet combination remains under regulatory development for specific rare-disease indications.